Launch of chimeric anti-mouse PD1 and PD-L1 recombinant antibodies
Leinco Technologies Highlights Launch of the new mAbMods™ chimeric anti-mouse PD1 and PD-L1 recombinant antibodies for use in in vivo functional studies ST. LOUIS, April 17, 2023 –Leinco Technologies (“Leinco”) ( St. Louis, MO), a [...]
Antibodies Targeting an Array of Infectious Diseases: Leinco and VUMC Advance Research and Diagnostics
Strategic Collaboration: Leinco Technologies and Vanderbilt University Medical Center ST. LOUIS, October 19, 2021 –Leinco Technologies, Inc (Leinco), a leading contract development manufacturing organization (CDMO) and life science tools company, today announced an agreement with [...]
Development of novel COVID-19 diagnostic tools
Leinco Technologies, Inc. and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools LA JOLLA, CA— La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to [...]
Launch of COVID-19 Neutralization MICRO-ELISA Assay
Leinco Technologies and ADMA Biologics Highlights Launch of COVID-19 ImmunoRank™ Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma Leinco Technologies ("Leinco") ( St. Louis, MO), a biotechnology company and specialty manufacturer of antibodies, [...]
Leinco receives CODEX® licensing rights
Akoya Biosciences, Inc. and Leinco Technologies, Inc. Announce Strategic Partnership for Customized CODEX Antibody Panel Design and Validation ST. LOUIS, April 22, 2020-- Leinco Technologies (St. Louis, MO) and Akoya Biosciences, (Menlo Park, CA) have [...]
Strategic Partnership: Leinco Technologies and Vanderbilt University Medical Center
Development of rapid, point of care, immunodiagnostic test for detection of the SARS-CoV-2 (COVID-19) ST. LOUIS, April 16, 2020-- Leinco Technologies, Inc., a premier developer and manufacturer of leading-edge recombinant proteins, antibodies, conjugates and provider [...]